Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes

Monteiro, Wuelton Marcelo; Brito-Sousa, José Diego; Baía-da-Silva, Djane Clarys; Siqueira, André Machado; Val, Fernando; Daniel-Ribeiro, Cláudio Tadeu; Lacerda, Marcus Vinícius Guimarães

doi:10.1590/0037-8682-0155-2020

Cited by 21 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The best approach to introduce rapid therapy is to test drugs that are already available on the market, as these have a safety profile previously widely studied (Dorward and Gbinigie 2020;Singh et al 2020). Nevertheless, the pathophysiological characteristics of COVID-19 should be taken into consideration, since drugs, as an example of hydroxychloroquine and chloroquine, present a predisposition to the development of cardiotoxicity in patients with COVID-19 (Monteiro et al 2020;Driggin et al 2020;Mehra et al 2020).…”

Section: Nanotechnology For the Prevention And Treatment Of Covid-19mentioning

confidence: 99%

Pharmaceutical nanotechnology: which products are been designed against COVID-19?

Cavalcanti

Nogueira

2020

J Nanopart Res

View full text Add to dashboard Cite

The current pandemic COVID-19, caused by the SARS-CoV-2 virus, has been affecting thousands of people worldwide, promoting high numbers of deaths. With this, the world population is going through a process of changing habits, with social distance, improvement of hygiene techniques, to reduce the spread of the SARS-CoV-2 virus and, consequently, reduce the number of hospitalized people in serious condition, as well as the mortality rate. This scenario has been promoting a continuous search for researchers, in the most varied areas, for possible methods of prevention or cure. Specifically, in the field of pharmaceutical nanotechnology, a variety of products are being developed against SARS-CoV-2. Under these circumstances, we propose here an exposition of some of the nanotechnological products (nanoscale between 1 to 1000 nm) currently designed for the detection of the virus, for the prevention and treatment of COVID-19, in addition to equipment for personal protection. We believe that pharmaceutical nanotechnology will be a valuable tool in the disease from the development of products that guarantee our protection against the SARS-CoV-2 virus.

show abstract

Section: Nanotechnology For the Prevention And Treatment Of Covid-19mentioning

confidence: 99%

Pharmaceutical nanotechnology: which products are been designed against COVID-19?

Cavalcanti

Nogueira

2020

J Nanopart Res

View full text Add to dashboard Cite

show abstract

“…In a randomized double-masked, phase IIb clinical trial (ChlorCovid-19 Study), with 81 adults who were hospitalized with SARS-CoV-2, preliminary findings suggest that the highest dose of chloroquine (600 mg, 2x/day, for 10 days, total dose of 12 g) should not be recommended for critically ill patients with COVID-19 due to security risk. These findings prematurely interrupted the recruitment of patients for this study (17,82,83).…”

Section: Chloroquine and Hydroxychloroquinementioning

confidence: 99%

Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences

et al. 2020

View full text Add to dashboard Cite

The pandemic caused by the new coronavirus (SARS-Cov-2) has encouraged numerous in vitro studies and clinical trials around the world, with research groups testing existing drugs, novel drug candidates and vaccines that can prevent or treat infection caused by this virus. The urgency for an effective therapy is justified by the easy and fast viral transmission and the high number of patients with severe respiratory distress syndrome who have increasingly occupied intensive care hospital beds, leading to a collapse in health systems in several countries. However, to date, there is no sufficient evidence of the effectiveness of any researched therapy. The off-label or compassionate use of some drugs by health professionals is a reality in all continents, whose permission by regulatory agencies has been based on the results of some clinical trials. In order to guide decision-making for the treatment of COVID-19, this review aims to present studies and guidelines on the main therapies that have been and are currently being tested against SARS-CoV-2 and to critically analyze the reported evidences.

show abstract

“…antibody, molecular markers and gene based therapies) 17 . There is a recurring argument emphasizing the HCQ perceived safety and low cost [18][19][20] . Nevertheless, when a treatment is unequivocally effective, we do use it despite adverse effects and despite the associated cost.…”

Section: The Fragile Biological Plausibilitymentioning

confidence: 99%

Hydroxychloroquine for the treatment of COVID-19: an approach based on the philosophy of science and heuristics

Solla

2020

Evidence

View full text Add to dashboard Cite

Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes

Cited by 21 publications

References 11 publications

Pharmaceutical nanotechnology: which products are been designed against COVID-19?

Pharmaceutical nanotechnology: which products are been designed against COVID-19?

Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences

Hydroxychloroquine for the treatment of COVID-19: an approach based on the philosophy of science and heuristics

Contact Info

Product

Resources

About